Acambis completes enrollment of Phase 3 JE vaccine trials ahead of schedule
Advertisement
Acambis plc announced that it has completed enrolment into two pivotal Phase 3 trials of its investigational vaccine against Japanese encephalitis (JE), ChimeriVax-JE, ahead of schedule. With this milestone met, Acambis remains on track for preparing the ChimeriVax-JE licence applications for submission in India and Australia in 2007.
More than 2,800 healthy adults are involved in the two Phase 3 trials, which are designed to provide comprehensive safety data and to evaluate the neutralising antibody responses of a single-dose of ChimeriVax-JE compared to JE-VAX®, a licensed three-dose JE vaccine. The multi-centre trials were initiated in November 2005 and are being conducted in Australia and the US.
Acambis' Chief Executive Officer Gordon Cameron commented: "We are making rapid progress towards our goal of submitting licence applications for Australia and India next year. With enrolment into the Phase 3 trials completed earlier than planned, we have taken an important step toward addressing the unmet medical need for a convenient, singledose and affordable vaccine for travellers and endemic populations where JE is an ever-present threat."
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Giant snails as pets can be dangerous - They are both scary and fascinating at the same time. Giant snails are becoming increasingly popular as pets. Now researchers are warning
Occupational_lung_disease
Category:Organoiodides

New approach drives bacteria to produce potential antibiotic, antiparasitic compounds - Researchers used a variety of techniques, including genome mining, to identify bacteria that produce defensive compounds in response to hormone exposure
